Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
In this medfyle
The 2024 ELN Less-Intensive AML classification is based on current genetic data from patients treated with less-intensive therapies. Due to the rarity of specific genetic rearrangements (e.g., translocations and inversions) in older patients, their prognostic impact could not be characterized. Additionally, this classification has limited applicability for patients with prior myeloproliferative neoplasms or previous exposure to hypomethylating agents (HMAs), including AML following myelodysplastic syndrome, as such patients were generally excluded from venetoclax (VEN)-based AML clinical trials. Analyses regarding low-dose cytarabine/VEN-based treatments and genomic determinants of outcomes have not yet been published.
About this Medfyle
©2024 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Nov 21;144(21):2169-2173.
